



**REGIONAL DRUG AND THERAPEUTICS CENTRE
(NEWCASTLE)**

COST COMPARISON CHARTS

July 2019

**16/17 Framlington Place
Newcastle upon Tyne
NE2 4AB**

INTRODUCTION

Charts are organised by BNF classification and show comparative costs at basic NHS prices (as of July 2019) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year¹ of treatment at a standard daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some drug groups – such as ACE inhibitors – doses may vary according to indication. Additionally, in some therapeutic areas – such as antibacterial drugs – the duration of treatment may differ from that shown.

The cost comparison charts are also available in Excel format to all stakeholders (under password protection) on our NHS website: <http://rdtc.nhs.uk/>

The contents table on the following page has been formatted so that you can quickly navigate to specific charts by holding the cursor over the chart title and clicking your left mouse button whilst holding down the “Ctrl” key.

NOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES

¹ 1 year in this case is equal to 364 days rather than 365 when 1 month equals 28 days.


To navigate to the chart required, hover the cursor over the section required, press CTRL and click with the left mouse button.

| CONTENTS by BNF 74 classification | Page |
|--|-------------|
| 1.1.1 Dyspepsia and gastro-oesophageal reflux disease..... | 5 |
| 1.2 Antispasmodics and other drugs altering gut motility | 5 |
| 1.3 Antisecretory drugs and mucosal protectants | 6 |
| 1.4 Acute diarrhoea..... | 7 |
| Chronic diarrhoea | 7 |
| 1.5.1 Aminosalicylates | 8 |
| 1.5.2 Rectal foams | 9 |
| 1.6 Laxatives | 10 |
| 2.2 Diuretics | 11 |
| 2.4 Beta-adrenoceptor blocking drugs..... | 12 |
| 2.5.4 Alpha-adrenoceptor blocking drugs | 12 |
| 2.5.5 Drugs affecting the renin-angiotensin system | 13 |
| 2.6.1/2.6.3 Nitrates and other antianginal drugs..... | 14 |
| 2.6.2 Calcium-channel blockers..... | 15 |
| 2.8 Anticoagulants | 16 |
| 2.9 Antiplatelet drugs | 17 |
| 2.12 Lipid-regulating drugs | 18 |
| 3.1 Bronchodilators | 19 |
| 3.2 Corticosteroids | 20 |
| 3.2 Corticosteroid & Bronchodilator Inhalers | 21 |
| 3.1 & 3.2 Inhaled therapy licensed for COPD..... | 22 |
| 3.3 Cromoglicate & related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors..... | 23 |
| 3.4.1 Antihistamines..... | 23 |
| 4.1 Hypnotics & anxiolytics | 24 |
| 4.2 Atypical antipsychotics – maintenance doses (adults with psychosis)..... | 25 |
| 4.2 Atypical antipsychotics – Low doses | 26 |
| 4.3 Antidepressant drugs..... | 27 |
| 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - Stimulant | 28 |
| 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Stimulant - Methylphenidate MR only | 29 |
| 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Non-Stimulant..... | 30 |
| 4.6 Drugs used in nausea and vertigo | 30 |
| 4.7 Analgesics..... | 31 |
| 4.7.2 Opioid analgesics..... | 32 |
| 4.7.2 Opioid analgesics – patches only | 33 |
| 4.7.2 MR Opioid analgesics | 34 |


| | |
|---|----|
| 4.7.2 Strong opioid analgesics – equipotent dose cost per 24 hours | 35 |
| 4.7.3 Neuropathic pain..... | 36 |
| 4.7.4.1 Antimigraine drugs (acute)..... | 36 |
| 4.8 Antiepileptic drugs..... | 37 |
| 4.9 Drugs used in parkinsonism and related disorders - Dopamine-receptor agonists..... | 38 |
| 4.9 Drugs used in parkinsonism and related disorders - Levodopa, COMT and MAO-B inhibitors | 39 |
| 4.10.2 Nicotine dependence | 40 |
| 4.11 Drugs for dementia | 41 |
| 5 Miscellaneous antimicrobial and anthelmintic drugs | 42 |
| 5.1.1 Penicillins | 42 |
| 5.1.2 Cephalosporins | 43 |
| 5.1.3 Tetracyclines..... | 43 |
| 5.1.12 Quinolones..... | 44 |
| 5.2 Miscellaneous antifungal drugs (including topical and gynaecological) | 44 |
| 6.1.1 Insulins (prefilled pens and cartridges) | 45 |
| Needles For Pre-Filled And Reusable Insulin Pens - 4mm to 6mm | 46 |
| Needles For Pre-Filled And Reusable Insulin Pens - 8mm | 47 |
| Blood lancets | 48 |
| 6.1.6 Blood glucose monitoring – cost of 50 tests more than £10..... | 49 |
| 6.1.6 Blood glucose monitoring – cost of 50 tests below £10..... | 50 |
| 6.1.2 Antidiabetic drugs | 51 |
| 6.1.2 Antidiabetic drugs – Newer agents | 52 |
| 6.4.1 Female sex hormones and their modulators – Combination HRT preparations | 53 |
| 6.4.1 Female sex hormones and their modulators – Oestrogen only HRT patches | 54 |
| 6.4.1 Female sex hormones and their modulators – Oestrogen only HRT options | 55 |
| 6.6.2 Bisphosphonates and other drugs affecting bone metabolism..... | 56 |
| 7.3 Contraceptives – combined hormonal contraceptives..... | 57 |
| 7.3 Contraceptives – Progestogen-only contraceptives | 58 |
| 7.4.1 Drugs for urinary retention | 59 |
| 7.4.2 Drugs for urinary frequency, enuresis and incontinence | 60 |
| 7.4.5 Drugs for erectile dysfunction | 61 |
| 8.3.4.2 Prostate cancer..... | 61 |
| 9 Baby milks - Specialised formulas - Infant and child per 100g..... | 62 |
| 9.6.4 Calcium and vitamin D..... | 63 |
| 9.6.4 Vitamin D preparations - prevention | 63 |
| 9.6.4 Vitamin D preparations – treatment..... | 64 |
| 10.1.1 Non-steroidal anti-inflammatory drugs..... | 65 |
| 10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices | 66 |
| 11.4.2 Other anti-Inflammatory preparations..... | 66 |

| | |
|--|----|
| 11.6 Treatment of Glaucoma | 67 |
| 11.8.1 Tear Deficiency, Ocular Lubricants, and Astringents | 68 |
| 12.2.1 Nasal steroids | 68 |
| 13.2.1 Emollients (by volume) | 69 |
| 13.2.1 Emollients per 100g/ml | 70 |
| 13.2.1.1 Emollient bath and shower preparations per 100g/ml | 71 |
| 13.4 Topical Corticosteroids | 72 |
| 13.4 Topical Corticosteroids with antimicrobial | 73 |
| Topical scalp preparations/Shampoos for eczema and psoriasis | 73 |
| 13.5.2 Steroid and vitamin D topical preparations | 74 |
| 13.6.1 Topical preparations for acne | 74 |
| Stoma adhesive removers | 75 |
| Patent expiry table July 2019 to June 2020..... | 76 |

1.1.1 Dyspepsia and gastro-oesophageal reflux disease




1.2 Antispasmodics and other drugs altering gut motility




[Contents](#)


1.3 Antisecretory drugs and mucosal protectants


[Contents](#)

1.4 Acute diarrhoea




Chronic diarrhoea




[Contents](#)

1.5.1 Aminosalicylates




[Contents](#)

1.5.2 Rectal foams




[Contents](#)

1.6 Laxatives




[Contents](#)

2.2 Diuretics




[Contents](#)

2.4 Beta-adrenoceptor blocking drugs




2.5.4 Alpha-adrenoceptor blocking drugs




[Contents](#)

2.5.5 Drugs affecting the renin-angiotensin system




[Contents](#)

2.6.1/2.6.3 Nitrates and other antianginal drugs



[Contents](#)

2.6.2 Calcium-channel blockers




[Contents](#)

2.8 Anticoagulants




[Contents](#)

2.9 Antiplatelet drugs


[Contents](#)

2.12 Lipid-regulating drugs




[Contents](#)

3.1 Bronchodilators




[Contents](#)

3.2 Corticosteroids




[Contents](#)

3.2 Corticosteroid & Bronchodilator Inhalers




[Contents](#)


3.1 & 3.2 Inhaled therapy licensed for COPD

[Contents](#)

3.3 Cromoglicic acid & related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors




3.4.1 Antihistamines




[Contents](#)

4.1 Hypnotics & anxiolytics



[Contents](#)


4.2 Atypical antipsychotics – maintenance doses (adults with psychosis)



N.B.: Asenapine is only intended for use in acute crisis and not licensed for maintenance therapy


[Contents](#)

4.2 Atypical antipsychotics – Low doses




[Contents](#)

4.3 Antidepressant drugs




[Contents](#)

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - Stimulant




[Contents](#)

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Stimulant - Methylphenidate MR only




[Contents](#)

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder – Non-Stimulant




[Contents](#)

4.6 Drugs used in nausea and vertigo




[Contents](#)

4.7 Analgesics




[Contents](#)

4.7.2 Opioid analgesics




[Contents](#)

4.7.2 Opioid analgesics – patches only




[Contents](#)

4.7.2 MR Opioid analgesics




[Contents](#)

4.7.2 Strong opioid analgesics – equipotent dose cost per 24 hours




[Contents](#)

4.7.3 Neuropathic pain




[Contents](#)

4.7.4.1 Antimigraine drugs (acute)




[Contents](#)

4.8 Antiepileptic drugs




[Contents](#)

4.9 Drugs used in parkinsonism and related disorders - Dopamine-receptor agonists




[Contents](#)

4.9 Drugs used in parkinsonism and related disorders - Levodopa, COMT and MAO-B inhibitors




[Contents](#)

4.10.2 Nicotine dependence




[Contents](#)

4.11 Drugs for dementia




[Contents](#)

5 Miscellaneous antimicrobial and anthelmintic drugs




5.1.1 Penicillins




[Contents](#)

5.1.2 Cephalosporins




5.1.3 Tetracyclines




[Contents](#)

5.1.12 Quinolones




5.2 Miscellaneous antifungal drugs (including topical and gynaecological)




[Contents](#)

6.1.1 Insulins (prefilled pens and cartridges)




[Contents](#)




[Contents](#)

Needles For Pre-Filled And Reusable Insulin Pens - 4mm to 6mm




[Contents](#)


Needles For Pre-Filled And Reusable Insulin Pens - 8mm



[Contents](#)


Blood lancets[Contents](#)

6.1.6 Blood glucose monitoring – cost of 50 tests more than £10




[Contents](#)

6.1.6 Blood glucose monitoring – cost of 50 tests below £10




[Contents](#)

6.1.2 Antidiabetic drugs


[Contents](#)

6.1.2 Antidiabetic drugs – Newer agents




[Contents](#)

6.4.1 Female sex hormones and their modulators – Combination HRT preparations




[Contents](#)

6.4.1 Female sex hormones and their modulators – Oestrogen only HRT patches




[Contents](#)

6.4.1 Female sex hormones and their modulators – Oestrogen only HRT options




[Contents](#)

6.6.2 Bisphosphonates and other drugs affecting bone metabolism



[Contents](#)


7.3 Contraceptives – combined hormonal contraceptives



[Contents](#)

For a more detailed comparison of contraceptives, access the excel version of the cost comparison charts via the RDTC website (link available via the title page). This is available to stakeholders only under password protection


7.3 Contraceptives – Progestogen-only contraceptives



[Contents](#)


For a more detailed comparison of contraceptives, access the excel version of the cost comparison charts via the RDTC website (link available via the title page). This is available to stakeholders only under password protection

7.4.1 Drugs for urinary retention




[Contents](#)


7.4.2 Drugs for urinary frequency, enuresis and incontinence


[Contents](#)

7.4.5 Drugs for erectile dysfunction




8.3.4.2 Prostate cancer




[Contents](#)

9 Baby milks - Specialised formulas - Infant and child per 100g




[Contents](#)

9.6.4 Calcium and vitamin D




9.6.4 Vitamin D preparations - prevention




[Contents](#)

9.6.4 Vitamin D preparations – treatment




[Contents](#)


10.1.1 Non-steroidal anti-inflammatory drugs


[Contents](#)

10.3.2 Rubefaciants, topical NSAIDs, capsaicin, and poultices




11.4.2 Other anti-inflammatory preparations




[Contents](#)

11.6 Treatment of Glaucoma




[Contents](#)

11.8.1 Tear Deficiency, Ocular Lubricants, and Astringents




[Contents](#)

12.2.1 Nasal steroids




[Contents](#)

13.2.1 Emollients (by volume)



[Contents](#)

13.2.1 Emollients per 100g/ml




[Contents](#)

13.2.1.1 Emollient bath and shower preparations per 100g/ml



[Contents](#)

13.4 Topical Corticosteroids




[Contents](#)

13.4 Topical Corticosteroids with antimicrobial




Topical scalp preparations/Shampoos for eczema and psoriasis




[Contents](#)


13.5.2 Steroid and vitamin D topical preparations



13.6.1 Topical preparations for acne



[Contents](#)

Stoma adhesive removers

[Contents](#)

Patent expiry table July 2019 to June 2020

Expiry dates below take account of the SPC and any paediatric extension. The table also indicates where a licence for a generic/biosimilar product is in the latter stages of the EU licensing process or is already available in the EU. However, it does not follow that a generic/biosimilar product will be available in the UK as patent issues differ between countries. Patent legislation is complex and the information below should be used as a guide only.

Note that patent expiries are subject to change when new licence extensions (SPC or paediatric) are granted to the originator product or if court decisions alter the patent status of a drug. In addition, the patent expiries detailed only cover the basic, manufacturing patent. Additional patents on formulations and uses can influence when a generic or biosimilar becomes available commercially.

Patent expiry date may not give an accurate date as to when a generic version will actually be marketed in the UK, once a generic has been granted a product licence.

| Drug | BNF | Patent expiry date * = UK patent only, no SPC | Date includes paediatric extension | Generic or biosimilar available/ in development | Commissioning route |
|--------------------------------|-----|---|------------------------------------|---|---------------------|
| Fosamprenavir | 5 | 2019 Jul | | | NHS England |
| Roflumilast | 3 | 2019 Jul | | | CCG |
| Insulin glulisine | 6 | 2019 Sep | | | CCG |
| Atazanavir | 5 | 2019 Sep | Yes | Yes | NHS England |
| Colesevelam | 2 | 2019 Sep | Yes | | CCG |
| Cinacalcet | 9 | 2019 Oct | | Yes | NHS England |
| Rasagiline | 4 | 2019 Oct | | Yes | CCG |
| Abacavir + lamivudine (Kivexa) | 5 | 2019 Dec | | | NHS England |
| Posaconazole | 5 | 2019 Dec | | | NHS England |
| Asenapine | 4 | 2020 Feb | | | CCG |
| Fosaprepitant | 4 | 2020 Feb | | | NHS England |
| Tenofovir + emtricitabine | 5 | 2020 Feb | | Yes | NHS England |
| Ziconotide | 4 | 2020 Feb | | | NHS England |
| Dexrazoxane | 8 | 2020 Mar | | | NHS England |
| Erlotinib HCl | 8 | 2020 Mar | | Yes | NHS England |
| Aliskiren | 2 | 2020 Apr | | | CCG |
| Eculizumab | 9 | 2020 Apr | | | NHS England |
| Temsirolimus | 8 | 2020 Apr | | | NHS England |

| Drug | BNF | Patent expiry date * = UK patent only, no SPC | Date includes paediatric extension | Generic or biosimilar available/ in development | Commissioning route |
|-------------|------------|--|---|--|----------------------------|
| Tipranavir | 5 | 2020 May | | | NHS England |
| Tocilizumab | 10 | 2020 Jun | | | Depends on indication |
| Bevacizumab | 8 | 2020 Jun | Yes | Yes | NHS England |